Evidence map›Paper›PMID 28960263›Full record

SynthesisCancer2018

Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.

Rathi N Pillai, Madhusmita Behera, Taofeek K Owonikoko, Alice O Kamphorst, Suchita Pakkala, Chandra P Belani, Fadlo R Khuri, Rafi Ahmed, Suresh S Ramalingam

Registry-linked trialAbstract readComparative StudySystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05812274 (A Phase IV Study of Apricity C.A.R.E. Program for Cancer Adverse Events Rapid Evaluation to Improve Treatment Outcomes of Ethnic/Racial Minority Non-small Cell Lung Cancer), which is not on this map. Cited by 193 papers, 19 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
193citing papers in PubMed, 19 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05812274 naterminatednot on this mapstarted 2023, after this paper: background citation

A Phase IV Study of Apricity C.A.R.E. Program for Cancer Adverse Events Rapid Evaluation to Improve Treatment Outcomes of Ethnic/Racial Minority Non-small Cell Lung Cancer (NSCLC) Patients Receiving Immunotherapy

TypeinterventionalSponsorColumbia UniversityRan2023 to 2025Enrolled30ConditionsNon Small Cell Lung CancerArmsApricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation
3 · Its place in the literature

Who cites it

193 citing papers in PubMed, 19 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Guideline
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer.European respiratory review : an official journal of the European Respiratory Society · 2019
    Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Trial

133 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Rathi N PillaiDepartment of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Madhusmita BeheraDepartment of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Taofeek K OwonikokoDepartment of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Alice O KamphorstEmory Vaccine Center, Department of Microbiology and Immunology, Emory University, Atlanta, Georgia.
Suchita PakkalaDepartment of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Chandra P BelaniPennsylvania University, Penn State Hershey Cancer Institute, Hershey, Pennsylvania.
Fadlo R KhuriDepartment of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.ORCID 0000-0003-4171-3392
Rafi AhmedEmory Vaccine Center, Department of Microbiology and Immunology, Emory University, Atlanta, Georgia.
Suresh S RamalingamDepartment of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.ORCID 0000-0002-0757-3106

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science CenterU10CA180950 · NCI · EMORY UNIVERSITY · PI RAMALINGAM, SURESH S · 2014 to 2018
$2.9M
Winship Cancer Institute, National Clinical Trials Network Lead Academic ParticipU10CA180864 · NCI · EMORY UNIVERSITY · PI BEITLER, JONATHAN, RAMALINGAM, SURESH S · 2014 to 2018
$2.9M
NCI NIH HHS P30 CA138292NCI NIH HHS U10 CA180864NCI NIH HHS U10 CA180950
6 · The paper itself

Abstract

backgroundMonoclonal antibodies against programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) are effective therapies in patients with non-small cell lung cancer (NSCLC). Herein, the authors performed a systematic review investigating differences in the toxicities of PD-1 and PD-L1 inhibitors.

methodsAn electronic literature search was performed of public databases (MEDLINE, Excerpta Medica dataBASE [EMBASE], and Cochrane) and conference proceedings for trials using PD-1 inhibitors (nivolumab and pembrolizumab) and PD-L1 inhibitors (atezolizumab, durvalumab, and avelumab) in patients with NSCLC. A formal systematic analysis was conducted with Comprehensive Meta-Analysis software (version 2.2). Clinical and demographic characteristics, response, and toxicity data were compared between both groups.

resultsA total of 23 studies reported between 2013 and 2016 were eligible for analysis. The total number of patients evaluated for toxicities was 3284 patients in the PD-1 group and 2460 patients in the PD-L1 group. The baseline patient characteristics of the 2 groups were similar, although there was a trend toward increased squamous histology in the group treated with PD-L1 (32% vs 25%; P = .6). There was no difference in response rate noted between PD-1 (19%) and PD-L1 (18.6%) inhibitors (P = .17). The incidence of overall adverse events (AEs) was comparable between the PD-1 and PD-L1 inhibitors (64% [95% confidence interval (95% CI), 63%-66%] vs 66% [95% CI, 65%-69%]; P = .8). Fatigue was the most frequently reported AE with both classes of drugs. Patients treated with PD-1 inhibitors were found to have a slightly increased rate of immune-related AEs (16% [95% CI, 14%-17%] vs 11% [95% CI, 10%-13%]; P = .07) and pneumonitis (4% [95% CI, 3%-5%] vs 2% [95% CI, 1%-3%]; P = .01) compared with patients who received PD-L1 inhibitors.

conclusionsIn this systematic review involving 5744 patients with NSCLC, the toxicity and efficacy profiles of PD-1 and PD-L1 inhibitors appear to be similar. Cancer 2018;124:271-7. © 2017 American Cancer Society.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedB7-H1 AntigenCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedProgrammed Cell Death 1 ReceptorAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedatezolizumabB7-H1 AntigenpembrolizumabProgrammed Cell Death 1 Receptoradverse eventsimmune checkpoint inhibitorsimmune-related adverse eventsnon-small cell lung cancer (NSCLC)

Identifiers

PMID28960263
PMCPMC5761314

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.